

Thomas F Patterson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6947579/publications.pdf>

Version: 2024-02-01

108
papers

27,115
citations

34105

52
h-index

28297

105
g-index

132
all docs

132
docs citations

132
times ranked

14668
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-1821.	5.8	4,375
2	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. <i>New England Journal of Medicine</i> , 2002, 347, 408-415.	27.0	3,048
3	Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2008, 46, 327-360.	5.8	2,432
4	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, e1-e60.	5.8	1,861
5	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
6	Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). <i>Clinical Infectious Diseases</i> , 2010, 50, 1101-1111.	5.8	1,281
7	Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. <i>Clinical Infectious Diseases</i> , 2010, 50, 1091-1100.	5.8	1,194
8	Practice Guidelines for Diseases Caused by <i>Aspergillus</i> . <i>Clinical Infectious Diseases</i> , 2000, 30, 696-709.	5.8	757
9	Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial. <i>Clinical Infectious Diseases</i> , 2007, 44, 2-12.	5.8	724
10	Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes. <i>Medicine (United States)</i> , 2000, 79, 250-260.	1.0	696
11	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet</i> , The, 2016, 387, 760-769.	13.7	695
12	Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1563-1571.	5.8	617
13	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	9.1	586
14	Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign. <i>Clinical Infectious Diseases</i> , 2007, 44, 373-379.	5.8	524
15	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. <i>Clinical Infectious Diseases</i> , 2008, 47, 674-683.	5.8	368
16	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, 433-442.	5.8	295
17	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. <i>Journal of Infection</i> , 2006, 53, 337-349.	3.3	290
18	Aspergillosis. <i>Infectious Disease Clinics of North America</i> , 2002, 16, 875-894.	5.1	284

#	ARTICLE	IF	CITATIONS
19	Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2564-2568.	3.2	281
20	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	8.2	278
21	In Vitro Activity of Caspofungin against <i>Candida albicans</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3591-3596.	3.2	276
22	Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2010, 50, 1559-1567.	5.8	269
23	Invasive Non- <i>Aspergillus</i> Mold Infections in Transplant Recipients, United States, 2001â€“2006. <i>Emerging Infectious Diseases</i> , 2011, 17, 1855-1864.	4.3	250
24	Antifungal Resistance in Pathogenic Fungi. <i>Clinical Infectious Diseases</i> , 2002, 35, 1073-1080.	5.8	229
25	Disruption of a Nonribosomal Peptide Synthetase in <i>Aspergillus fumigatus</i> Eliminates Gliotoxin Production. <i>Eukaryotic Cell</i> , 2006, 5, 972-980.	3.4	208
26	Advances and challenges in management of invasive mycoses. <i>Lancet, The</i> , 2005, 366, 1013-1025.	13.7	201
27	Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. <i>Cancer</i> , 2006, 107, 2888-2897.	4.1	200
28	In Vitro Interaction of Caspofungin Acetate with Voriconazole against Clinical Isolates of <i>Aspergillus</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3039-3041.	3.2	176
29	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases, The</i> . 2021, 21, e246-e257.	9.1	167
30	<i>Aspergillus</i> Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing. <i>Clinical Infectious Diseases</i> , 2015, 61, 1293-1303.	5.8	157
31	Detection and Significance of Fluconazole Resistance in Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected Patients. <i>Journal of Infectious Diseases</i> , 1996, 174, 821-827.	4.0	114
32	Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome. <i>Clinical Infectious Diseases</i> , 2005, 41, 1448-1452.	5.8	106
33	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	8.2	106
34	Fungal disease of the nose and paranasal sinuses. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 321-326.	2.9	103
35	Treatment of Experimental Invasive Aspergillosis with Novel Amphotericin B/Cholesterol-Sulfate Complexes. <i>Journal of Infectious Diseases</i> , 1989, 159, 717-724.	4.0	100
36	Invasive Aspergillosis. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 125-142.	5.1	97

#	ARTICLE	IF	CITATIONS
37	Aspergillosis. Infectious Disease Clinics of North America, 2021, 35, 415-434.	5.1	96
38	Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience. Antimicrobial Agents and Chemotherapy, 2009, 53, 2223-2224.	3.2	85
39	Antifungal Combinations against <i>Candida albicans</i> Biofilms In Vitro. Antimicrobial Agents and Chemotherapy, 2003, 47, 3657-3659.	3.2	84
40	Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clinical Infectious Diseases, 2015, 60, 713-720.	5.8	75
41	Repurposing auranofin as an antifungal: <i>in vitro</i> activity against a variety of medically important fungi. Virulence, 2017, 8, 138-142.	4.4	75
42	Coronavirus Disease 2019-associated Invasive Fungal Infection. Open Forum Infectious Diseases, 2021, 8, ofab510.	0.9	75
43	Efficacy of Voriconazole in a Guinea Pig Model of Disseminated Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy, 2000, 44, 2865-2868.	3.2	74
44	The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity <i>in vitro</i> and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 7115-7127.	3.2	69
45	Nosocomial Outbreak of <i>Exophiala jeanselmei</i> Fungemia Associated with Contamination of Hospital Water. Clinical Infectious Diseases, 2002, 34, 1475-1480.	5.8	68
46	Screening a Repurposing Library for Inhibitors of Multidrug-Resistant <i>Candida auris</i> Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	68
47	Assessment of <i>Aspergillus fumigatus</i> Burden in Pulmonary Tissue of Guinea Pigs by Quantitative PCR, Galactomannan Enzyme Immunoassay, and Quantitative Culture. Antimicrobial Agents and Chemotherapy, 2008, 52, 2593-2598.	3.2	66
48	Nosocomial Fungemia Due to <i>Exophiala jeanselmei</i> var. <i>jeanselmei</i> and a <i>Rhinocladiella</i> Species: Newly Described Causes of Bloodstream Infection. Journal of Clinical Microbiology, 2001, 39, 514-518.	3.9	62
49	Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa242.	0.9	62
50	Efficacy of SCH56592 in a Rabbit Model of Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy, 2000, 44, 780-782.	3.2	59
51	The epidemiology of non- <i>albicans</i> <i>Candida</i> in oropharyngeal candidiasis in HIV patients. Special Care in Dentistry, 2000, 20, 178-181.	0.8	55
52	Pulmonary Aspergillosis. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 103-110.	2.1	55
53	Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant <i>Candida albicans</i> . Antimicrobial Agents and Chemotherapy, 2011, 55, 3254-3260.	3.2	55
54	Detection of Urinary Excreted Fungal Galactomannan-like Antigens for Diagnosis of Invasive Aspergillosis. PLoS ONE, 2012, 7, e42736.	2.5	55

#	ARTICLE	IF	CITATIONS
55	Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3340-3347.	3.2	54
56	Hospital Epidemiologic Surveillance for Invasive Aspergillosis: Patient Demographics and the Utility of Antigen Detection. <i>Infection Control and Hospital Epidemiology</i> , 1997, 18, 104-108.	1.8	53
57	Standardization of an Experimental Murine Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3501-3503.	3.2	51
58	Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis. <i>Medical Mycology</i> , 2019, 57, S76-S84.	0.7	50
59	Comparison of Lateral Flow Technology and Galactomannan and (1 α '3)- β -D-Glucan Assays for Detection of Invasive Pulmonary Aspergillosis. <i>Vaccine Journal</i> , 2009, 16, 1844-1846.	3.1	48
60	Emergence of Azole Resistance in <i>Aspergillus</i> . <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 673-680.	2.1	45
61	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 757-763.	3.0	40
62	Pulmonary Aspergillosis: Recent Advances. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 673-681.	2.1	38
63	Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 353-357.	3.0	35
64	Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor β blocker adalimumab in cryptococcal pneumonia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 327-330.	1.8	33
65	Our 2014 approach to breakthrough invasive fungal infections. <i>Mycoses</i> , 2014, 57, 645-651.	4.0	32
66	New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 9.	3.5	32
67	Hospital Epidemiologic Surveillance for Invasive Aspergillosis: Patient Demographics and the Utility of Antigen Detection. <i>Infection Control and Hospital Epidemiology</i> , 1997, 18, 104-108.	1.8	32
68	Treatment of invasive aspergillosis: Polyenes, echinocandins, or azoles?. <i>Medical Mycology</i> , 2006, 44, 357-362.	0.7	31
69	Sequential or Combination Antifungal Therapy with Voriconazole and Liposomal Amphotericin B in a Guinea Pig Model of Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1567-1569.	3.2	29
70	Risk stratification for invasive aspergillosis: early assessment of host susceptibility. <i>Medical Mycology</i> , 2009, 47, S255-S260.	0.7	28
71	Detection and Measurement of Fungal Burden in a Guinea Pig Model of Invasive Pulmonary Aspergillosis by Novel Quantitative Nested Real-Time PCR Compared with Galactomannan and (1,3)- β -D-Glucan Detection. <i>Journal of Clinical Microbiology</i> , 2012, 50, 602-608.	3.9	28
72	A murine model of <i>Cryptococcus gattii</i> meningoencephalitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1432-1438.	3.0	25

#	ARTICLE	IF	CITATIONS
73	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	25
74	Cost Advantage of Voriconazole over Amphotericin B Deoxycholate for Primary Treatment of Invasive Aspergillosis. <i>Pharmacotherapy</i> , 2005, 25, 839-846.	2.6	23
75	Efficacy of Posaconazole as Treatment and Prophylaxis against <i>Fusarium solani</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1055-1059.	3.2	23
76	New Guinea Pig Model of Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3011-3013.	3.2	22
77	Development and Evaluation of a Calibrator Material for Nucleic Acid-Based Assays for Diagnosing Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2403-2405.	3.9	22
78	Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 970-976.	3.0	20
79	Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model. <i>Journal of Clinical Microbiology</i> , 2016, 54, 960-966.	3.9	19
80	Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	19
81	Extended-Interval Dosing of Rezafungin against Azole-Resistant <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	18
82	Diagnosis and Treatment of Invasive Fungal Infections in the Cancer Patient: Recent Progress and Ongoing Questions. <i>Clinical Infectious Diseases</i> , 2014, 59, S356-S359.	5.8	17
83	<i>Aspergillus</i> Polymerase Chain Reaction—An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, S95-S101.	5.8	17
84	What's new in antifungals. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 539-545.	3.1	16
85	SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease. <i>PLoS ONE</i> , 2021, 16, e0261656.	2.5	16
86	New Agents for Treatment of Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2002, 35, 367-369.	5.8	15
87	Case 22-2009. <i>New England Journal of Medicine</i> , 2009, 361, 287-296.	27.0	15
88	Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6703-6708.	3.2	15
89	Invasive mycoses: management and unmet medical needs. <i>Current Opinion in Infectious Diseases</i> , 2001, 14, 669-671.	3.1	14
90	Fungal Infections Potentiated by Biologics. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 389-411.	5.1	14

#	ARTICLE	IF	CITATIONS
91	Clinical utility and development of biomarkers in invasive aspergillosis. Transactions of the American Clinical and Climatological Association, 2011, 122, 174-83.	0.5	11
92	Animal Models In Mycology: What Have We Learned Over The Past 30 Years. Current Fungal Infection Reports, 2013, 7, 68-78.	2.6	9
93	Aspergillus Species. , 2010, , 3241-3255.		9
94	Current and future approaches to antifungal therapy. Current Opinion in Infectious Diseases, 2000, 13, 579-561.	3.1	6
95	Combination antifungal therapy. Pediatric Infectious Disease Journal, 2003, 22, 555-556.	2.0	6
96	The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and candida. Current Infectious Disease Reports, 2006, 8, 442-448.	3.0	6
97	Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection. Drug Development and Industrial Pharmacy, 2017, 43, 264-274.	2.0	6
98	Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis. Journal of Fungi (Basel, Switzerland), 2021, 7, 313.	3.5	6
99	Early use of antifungal therapy in high-risk patients. Current Opinion in Infectious Diseases, 2002, 15, 561-563.	3.1	4
100	Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA). Clinical Infectious Diseases, 2008, 46, T1-T36.	5.8	4
101	Aspergillus Species. , 2015, , 2895-2908.e4.		4
102	Aspergillus and Candida Infections in Bone Marrow Transplantation. Infectious Diseases in Clinical Practice, 1997, 6, 506-512.	0.3	3
103	Novel approaches to antifungal therapy. American Journal of Transplantation, 2018, 18, 287-288.	4.7	3
104	Assessment of Aspergillus fumigatus in Guinea Pig Bronchoalveolar Lavages and Pulmonary Tissue by Culture and Realtime Polymerase Chain Reaction Studies. International Journal of Molecular Sciences, 2012, 13, 726-736.	4.1	2
105	Polymeric Iron Chelator with Enhanced Iron Affinity as a Broad-Spectrum Antifungal Agent. ACS Applied Polymer Materials, 2021, 3, 6034-6039.	4.4	2
106	The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida. Current Fungal Infection Reports, 2007, 1, 5-11.	2.6	1
107	Antifungal Therapy. , 0, , 1423-1432.		0
108	Antifungal therapy. , 0, , 1344-1352.		0